Browse 80 tables and 55 figures spread through 142 Pages and in-depth TOC on "Therapeutic Drug Monitoring Market by Product (Consumables, Equipment), Technology (Immunoassays, Proteomic Technologies), Class of Drug (Antiepileptics, Antibiotics, Immunosuppressants), End User (Hospital Labs, Private Labs) - Global Forecast to 2020"
https://www.marketsandmarkets.com/Market-Reports/therapeutic-drug-monitoring-market-155350443.html
Early buyers will receive 10% customization on reports.

This report provides a detailed overview of the major drivers, restraints, challenges, opportunities, current market trends, and strategies impacting the therapeutic drug monitoring market along with the estimates and forecasts of the revenue.

The technological advances in tests used to monitor therapeutic drugs, increased knowledge of pharmacogenetics and pharmacokinetics of drugs, need for better healthcare in developing countries, and rising prevalence of psychiatric diseases and cancer are the major drivers for the therapeutic drug monitoring market. Adjunct technologies such as biomarker identification using proteomics to accurately identify clinical outcomes and genetic testing are expected to benefit the growth of the therapeutic drug monitoring market. However, high infrastructure costs and dearth of skilled resources may restrain the market growth.

In this report, the therapeutic drug monitoring market is broadly segmented by product, technology, class of drug, end user, and region. On the basis of product, the therapeutic drug monitoring market is divided into consumables and equipment. The equipment segment is further segmented into immunoassay analyzers, proteomic equipment, and other equipment.

On the basis of technology, the therapeutic drug monitoring market is categorized into three segments namely, immunoassays, proteomic technologies, and others. The immunoassays segment is classified into chemiluminescent assay (CLIA), cloned enzyme donor immunoassay (CEDIA), fluorescence polarization immunoassay (FPIA), particle-enhanced turbidimetric inhibition immunoassay (PETINIA), and others. The proteomic technologies segment is further split into liquid chromatography/mass spectrometry and gas chromatography/mass spectrometry.